Press release, Copenhagen, February 27, 2020
Newly founded PokeAcell signs licensing agreement with Technical University of Denmark (DTU) enabling development of a novel personalized cell therapy for cancer
PokeAcell, a newly founded immunotherapy company, has secured exclusive licensing rights to a proprietary technology, for personalized T cell therapy. The new technology can activate and grow cancer-specific T cells present in patient’s own blood and the cells can then be given back to the patient as fully personalized treatment. The T cell therapy hold the potential of curative treatment in Metastatic Melanoma and Merkel Cell carcinoma – two of the most severe skin cancers today and with potential in several other indications.
“We are founding PokeAcell with the mission to provide curative treatment to solid tumor patients with no available treatment today. We are pleased to sign this exclusive licensing agreement with DTU on the ImmPACT activation technology and further strengthen the development of personalized T cell therapy,” says Anne Reker Cordt, CEO and co-founder PokeAcell
PokeAcell is a spin out of DTU Health Technologies based on the distinct expertise of Prof. Sine R. Hadrup, PhD., who will receive the prestigious Elite Research Prize from the Ministry of Higher Education and Science at a ceremony later today.
Prof. Sine R. Hadrup – inventor and co-founder of PokeAcell, says: “T cells are the natural soldiers of the immune system and hold immense potential in the treatment of cancer. The ImmPACT technology create a personalized cell product with very beneficial properties and is now one step closer to helping patients in need of better treatment”.
PokeAcell is founded by an experienced team of science and business leaders and have established a strong advisory Board, which includes profiles such as John Haurum, biotech executive and board member and Inge Marie Svane, Prof, MD Herlev CCIT.
“In patients with metastatic cancers it can be very difficult for the immune system to overcome the influence of the cancer. T cell therapy has shown good results in clinical trials and PokeAcell’s T cell technology has a very interesting potential for extending T cell therapy to more patients with Metastatic Melanoma. I look forward to the results of the first clinical evaluation,” says Inge Marie Svane, Prof, MD Herlev CCIT.
PokeAcells is a Copenhagen based privately owned immunotherapy company. PokeAcell’s personalized T cell product is in pre-clinical evaluation and is in preparation for an investigator lead phase I in Metastatic Melanoma at Herlev CCIT.
Read more on www.pokeacell.com
Anne Reker Cordt, CEO PokeAcell, email: ARC@pokeacell.com, Phone: +45 53393007
Prof. Sine R. Hadrup, PhD., CSO PokeAcell, email: SRH@pokeacell.com, Phone: +45 27125221
PokeAcell is an immunotherapy company with a proprietary technology for personalized T cell therapy of late stage cancer, founded in Copenhagen, Denmark. PokeAcell’s proprietary technology activate and grow cancer-specific T cells present in patient’s own blood and give back the cells as fully personalized treatment. The T cell therapy hold the promise of curative treatment in Metastatic Melanoma and Merkel Cell carcinoma – two of the most severe skin cancers today and with potential in several other indications.
PokeAcell is a spin out of DTU Health Technologies based on the distinct expertise of Prof. Sine R. Hadrup, PhD., and her internationally recognized research in immunotherapies. The company is founded by an experienced team of science and business leaders with the vision to provide curative treatment to late stage cancer patients, where no treatment is available today.
Read more on www.pokeacell.com